MKI67 and neoplasm: Both Ki67 and BrdU immunohistochemistry analyses demonstrated a significant decrease in tumor cell proliferation levels in CM-1758 treatment group (Fig. 4e and f1, 2, 3 and 4; Supplementary Figs. S9e and S9f1, 2, 3 and 4).